NCT01965132 Korean College of Rheumatology Biologics and Targeted Therapy Registry
| NCT ID | NCT01965132 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Hospital |
| Condition | Rheumatoid Arthritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2012-12-01 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2012-12-01 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
We established a nationwide biologics and targeted synthetic DMARDs registry (in the form of an inception cohort) to study the safety profiles in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis patients receiving biologics or targeted synthetic DMARDs. As this registry is to observe the "real world" use of anti-rheumatic treatments under routine clinical practice, no hypothesis to prove is planned.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with RA, AS or PsA * RA deemed by their rheumatologist to require treatment with a biologic or targeted synthetic DMARDs or a conventional DMARD(s) * AS or PsA patients who are to initiate, restart or switch to a biologic agent or a targeted synthetic DMARD * Patients who provide a written consent of participating in this registry (data collection and review). Exclusion Criteria: * RA, AS, PsA patients who are already on biologics or targeted synthetic DMARDs upon screening
Contact & Investigator
Kichul Shin, MD
✉ kideb1@snu.ac.krEun Yeong Lee, MD
PRINCIPAL INVESTIGATOR
Seoul National University Hospital
Frequently Asked Questions
Who can join the NCT01965132 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rheumatoid Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01965132 currently recruiting?
Yes, NCT01965132 is actively recruiting participants. Contact the research team at kideb1@snu.ac.kr for enrollment information.
Where is the NCT01965132 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT01965132 clinical trial?
NCT01965132 is sponsored by Seoul National University Hospital. The principal investigator is Eun Yeong Lee, MD at Seoul National University Hospital. The trial plans to enroll 10,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.